ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France
Editorial Contributor
Senior Scientific Director
Executive Vice President
Director, Scientific Services
Scientific Director
Editorial Contributor
Executive Vice President, Educational Strategy
General Manager, Oncology
This program has been made available online.
Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)
Robert G. Gish, MD
Released: July 22, 2021
Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments
Stefan Zeuzem, MD
Released: July 22, 2021
Commentary from Nancy Reau on HDV and HBV
Nancy Reau, MD
Released: July 22, 2021
CCO slideset: key viral hepatitis studies EASL 2021, including treatment of HDV, HBV, HCV in in adults and children, linking patients to care, HBV cure, and more
Tarik Asselah, MD, PhD
Robert G. Gish, MD
Nancy Reau, MD
Stefan Zeuzem, MD
Released: July 15, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.